How the Fibrotic Lung Microenvironment Regulates Stem Cell Behavior: Immune Cues, Extracellular Matrix Remodeling,...

Pulmonary fibrosis (PF) is a chronic and progressive interstitial lung disease characterized by excessive extracellular matrix (ECM) deposition and remodeling of lung structures. Currently, no effective clinical treatments exist to reverse or halt the progression of PF. Consequently, there is an urgent need to identify novel therapeutic strategies for this complex disease. Stem cells, renowned for their self-renewal and multipotent differentiation capabilities, have garnered considerable attention for their potential therapeutic applications, particularly in regenerative medicine. The primary stem cell types investigated for PF treatment include mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and lung progenitor cells. Preclinical studies have demonstrated that these stem cells can reduce inflammation, modulate immune responses, and promote the repair of damaged lung tissue. Although stem cell transplantation shows promise in PF treatment, challenges such as safety, quality control, and therapeutic efficacy remain unresolved. Recent studies have highlighted that stem cells interact with and modify their transplanted environment, influencing their structural properties and chemical composition. These interactions strongly influence stem cell survival, phenotype, and therapeutic efficacy. Understanding these dynamics will inform the development of new strategies to improve the effectiveness of stem cell therapies for PF.